[ACOR] Acorda Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization: 1.15 B

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 18.15 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart ACOR

Refresh chart

Strongest Trends Summary For ACOR

ACOR is in the long-term down -62% below S&P in 15 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system in the United States. The company?s products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; Zanaflex Capsules and Zanaflex tablets, a short-acting drug for the management of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the management of neuropathic pain. It is also involved in developing Diazapam Nasal Spray for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase III clinical development program preparations for post-stroke deficits; NP-1998, a topical solution that is in phase III clinical trail for the treatment of neuropathic pain; AC105, which is in Phase II clinical trials for the treatment of SCI; Neuregulin Program that has completed Phase 1 clinical trial for the trea

Fundamental Ratios
Shares Outstanding46.07 M EPS-1.16 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 2.8% Sales Growth - Q/Q-15.29% P/E-14.87
P/E To EPS Growth P/S2.74 P/BV2.1 Price/Cash Per Share3.83
Price/Free Cash Flow16.48 ROA1.26% ROE2.53% ROI1.53%
Current Ratio3.47 Quick Ratio3.09 Long Term Debt/Equity0.96 Debt Ratio0.22
Gross Margin80.15% Operating Margin7.54% Net Profit Margin3.3% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities4.63 M Cash From Investing Activities-116.04 M Cash From Operating Activities-9.25 M Gross Profit90.84 M
Net Profit1000 K Operating Profit5.69 M Total Assets1.1 B Total Current Assets408.31 M
Total Current Liabilities460.01 M Total Debt292.68 M Total Liabilities540.27 M Total Revenue113.71 M
Technical Data
High 52 week32.6 Low 52 week13.8 Last close32.6 Last change7.24%
RSI96.12 Average true range1.73 Beta1.06 Volume622.39 K
Simple moving average 20 days27.01% Simple moving average 50 days34.29% Simple moving average 200 days35.16%
Performance Data
Performance Week23.72% Performance Month38.14% Performance Quart27.34% Performance Half57.11%
Performance Year92.9% Performance Year-to-date51.98% Volatility daily2.78% Volatility weekly6.22%
Volatility monthly12.76% Volatility yearly44.18% Relative Volume329.71% Average Volume497.09 K
New High New Low

News

2019-11-12 07:00:00 | Acorda Therapeutics Announces Departure of President, International & General Counsel

2019-11-08 10:21:43 | Is Acorda Therapeutics, Inc.'s NASDAQ:ACOR CEO Paid Enough Relative To Peers?

2019-11-07 11:08:04 | Zoetis ZTS Beats on Earnings in Q3, Reports In-Line Sales

2019-11-07 11:05:04 | Horizon Therapeutics' HZNP Q3 Earnings Beat Estimates

2019-11-07 11:04:04 | Esperion ESPR Reports Wider-Than-Expected Loss in Q3

2019-11-07 08:50:01 | Geron GERN Q3 Earnings Beat Estimates, Stock Gains 4.1%

2019-11-06 16:40:57 | Were Hedge Funds Right About Dumping Acorda Therapeutics Inc ACOR?

2019-11-06 16:28:46 | Edited Transcript of ACOR earnings conference call or presentation 4-Nov-19 9:30pm GMT

2019-11-06 10:56:03 | Perrigo PRGO Beats on Q3 Earnings, Tightens '19 EPS View

2019-11-06 10:34:03 | Intercept ICPT Earnings and Sales Miss Estimates in Q3

2019-11-05 11:45:04 | Acorda ACOR Q3 Earnings and Revenues Surpass Estimates

2019-11-05 11:09:04 | Agenus AGEN Q3 Earnings Beat Estimates, Revenues Up Y/Y

2019-11-04 17:25:10 | Acorda Therapeutics ACOR Reports Q3 Loss, Tops Revenue Estimates

2019-11-04 16:00:00 | Acorda Provides Update for Third Quarter Ended September 30, 2019

2019-11-04 11:18:04 | AMAG Q3 Loss Wider Than Expected, Revenues Lag Estimates

2019-11-01 14:49:06 | Repligen RGEN Beats on Q3 Earnings, Lifts 2019 Guidance

2019-11-01 12:07:04 | Agios' AGIO Q3 Loss Narrower Than Expected, Revenues Miss

2019-10-31 12:40:04 | Immunomedics IMMU Reports Wider-Than-Expected Loss in Q3

2019-10-31 12:33:04 | Vertex VRTX Q3 Earnings Beat, Revenues Lag Estimates

2019-10-31 11:54:03 | Medicines Company MDCO Incurs Wider-Than-Expected Q3 Loss

2019-10-31 09:26:01 | Insmed INSM in Focus: Stock Moves 7.1% Higher

2019-10-28 10:32:02 | Acorda Therapeutics ACOR Expected to Beat Earnings Estimates: Should You Buy?

2019-10-25 07:12:03 | The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug

2019-10-24 11:24:03 | Acorda ACOR to Post Q3 Earnings: What's in the Cards?

2019-10-24 07:36:58 | The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise

2019-10-23 16:00:00 | Acorda Therapeutics Implements Corporate Restructuring, Provides Third Quarter 2019 Update

2019-10-22 07:00:00 | Acorda Launches New Tool for People with Parkinson’s to Improve Communication About OFF Periods

2019-10-21 07:00:00 | Acorda Third Quarter 2019 Update: Webcast/Conference Call Scheduled for November 4, 2019

2019-10-07 10:00:49 | UPDATE 1-U.S. Supreme Court rejects Acorda appeal in MS drug patent fight

2019-10-03 09:00:01 | Acorda ACOR Upgraded to Buy: Here's What You Should Know

2019-09-26 08:40:12 | Medicines Company MDCO Jumps: Stock Rises 5.5%

2019-09-25 18:22:10 | Protalix Completes Enrollment in Third Fabry Disease Study

2019-09-25 18:18:10 | Menlo MNLO Completes Enrollment in Phase II Pruritus Study

2019-09-25 07:00:00 | Acorda Therapeutics to Present at the 2019 Cantor Healthcare Conference

2019-09-18 10:33:02 | Acceleron Discontinues Mid-Stage Muscular Dystrophy Study

2019-09-18 08:42:12 | Lexicon LXRX Catches Eye: Stock Jumps 7.3%

2019-09-18 07:00:00 | Acorda to Present Data at the International Congress of Parkinson’s Disease and Movement Disorders

2019-09-16 10:29:02 | Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease

2019-09-13 10:30:02 | Celgene's CELG Leukemia Candidate Meets Endpoints in Study

2019-09-13 08:42:12 | Ligand LGND Surges: Stock Moves 6.3% Higher

2019-09-12 08:35:12 | Immunomedics IMMU Looks Good: Stock Adds 6.1% in Session

2019-09-11 11:37:03 | Ultragenyx to Submit sBLA for Label Expansion of Crysvita

2019-09-10 09:01:01 | Adaptimmune ADAP Gets Orphan Drug Status for T-cell Therapy

2019-09-10 07:59:11 | Horizon's HZNP Eye Disease Drug Gets FDA's Priority Review

2019-09-09 15:51:30 | Did Changing Sentiment Drive Acorda Therapeutics's NASDAQ:ACOR Share Price Down A Painful 91%?

2019-09-03 11:00:03 | Acorda ACOR Down More Than 60% in 3 Months: Here's Why

2019-08-31 09:32:01 | Why Is Acorda ACOR Down 46.8% Since Last Earnings Report?

2019-08-23 09:15:01 | Alexion Pharmaceuticals ALXN Jumps: Stock Rises 7.5%

2019-08-23 07:38:11 | Retrophin Down on Neurological Disorder Drug Study Failure

2019-08-21 18:03:10 | Synlogic Discontinues Development of SYNB1020, Stock Down